

## Author index of volume 58

- Abdella, N., see Mojiminiyi, O.A. 58, 37  
 Abe, R., see Yamanouchi, K. 58, 11  
 Ahroni, J.H., see Wheeler, S.G. 58, 131  
 Akanji, A.O., see Mojiminiyi, O.A. 58, 37  
 Al Mohammedi, H., see Mojiminiyi, O.A. 58, 37  
 Altınbaş, M., see Çetin, M. 58, 97  
 Atsumi, Y., see Yamanouchi, K. 58, 11
- Babazono, T., see Ujihara, N. 58, 109  
 Baccetti, F., see Piaggese, A. 58, 1  
 Balkau, B., see Nakagami, T. 58, 73  
 Bayés, B., see Serra, A. 58, 149  
 Bayram, F., see Çetin, M. 58, 97  
 Bennett, P.H., see Li, G. 58, 193  
 Bhonde, R.R., see Risbud, M.V. 58, 155  
 Bonet, J., see Serra, A. 58, 149  
 Borch-Johnsen, K., see Nakagami, T. 58, 73  
 Boyko, E.J., see Wheeler, S.G. 58, 131  
 Brant, B.P., see Willi, S.M. 58, 87
- Carstensen, B., see Nakagami, T. 58, 73  
 Çetin, M., R. Çolak, F. Bayram, M. Altınbaş, A. Ünal, F. Keleştimur, High prevalence of diabetes in patients with pancreatic cancer in central Anatolia, Turkey 58, 97  
 Cheadle, A.D., see Hirsch, I.B. 58, 27  
 Ciaccio, S., see Piaggese, A. 58, 1  
 Çolak, R., see Çetin, M. 58, 97  
 Costi, D., see Piaggese, A. 58, 1
- Danawati, W., M. Sakaue, H. Taniguchi, Low prevalence of the substitution of adenine to guanine at the 3243 nucleotide position of mitochondrial DNA (MtDNA) among Indonesian diabetic subjects 58, 201  
 Daniel, M., K.G. Rowley, K. O'Dea, Fasting criteria for screening: test properties and agreement with glucose tolerance 58, 139  
 Daniels, A., see Wong, J. 58, 61  
 De Alwis, N.M.W., see De Silva, S.N.T. 58, 173  
 De Gregorio, S., see Piaggese, A. 58, 1
- Del Prato, S., see Piaggese, A. 58, 1  
 De Silva, M.W.A., see De Silva, S.N.T. 58, 173  
 De Silva, S.N.T., N. Weerasuriya, N.M.W. De Alwis, M.W.A. De Silva, D.J.S. Fernando, Excess maternal transmission and familial aggregation of Type 2 diabetes in Sri Lanka 58, 173
- Ellsworth, A., see Hirsch, I.B. 58, 27  
 Elston, R.C., see Wong, J. 58, 61  
 Erem, C., see Kavgaci, H. 58, 19  
 Evans, T.C., see Hirsch, I.B. 58, 27
- Fernando, D.J.S., see De Silva, S.N.T. 58, 173  
 Fujii, M., see Miyatake, N. 58, 101  
 Fukushima, H., see Kato, S. 58, 187
- Garvey, W.T., see Willi, S.M. 58, 87  
 Goldberg, H.I., see Hirsch, I.B. 58, 27  
 Golia, F., see Piaggese, A. 58, 1
- Hanson, U., see Persson, B. 58, 115  
 Hansson, L.-O., see Persson, B. 58, 115  
 Haraguchi, T., see Takahashi, T. 58, 123  
 Hasegawa, M., Y. Tang, H. Osawa, H. Onuma, T. Nishimiya, M. Ochi, Y. Terauchi, T. Kadowaki, H. Makino, Differential regulation of gene expression and insulin-induced activation of phosphodiesterase 3B in adipocytes of lean insulin-resistant IRS-1 (–/–) mice 58, 79  
 Herter, C.D., see Hirsch, I.B. 58, 27  
 Higashi, K., see Takahashi, T. 58, 123  
 Hirayama, M., see Ujihara, N. 58, 109  
 Hirsch, I.B., H.I. Goldberg, A. Ellsworth, T.C. Evans, C.D. Herter, S.D. Ramsey, M. Mullen, W.E. Neighbor, A.D. Cheadle, A multifaceted intervention in support of diabetes treatment guidelines: a controlled trial 58, 27  
 Hjertberg, R., see Persson, B. 58, 115  
 Holdaway, I.M., see Wong, J. 58, 61  
 Hori, S., see Kato, S. 58, 187  
 Howard, B.V., see Li, G. 58, 193  
 Hu, Y., see Li, G. 58, 193

- Hu, Z., see Li, G. 58, 193
- Ishiba, Y., see Kobayashi, J. 58, 167
- Ishii, A., see Ujihara, N. 58, 109
- Iwamoto, Y., see Nakagami, T. 58, 73
- Iwamoto, Y., see Ujihara, N. 58, 109
- Jiang, Y., see Li, G. 58, 193
- Kadowaki, T., see Hasegawa, M. 58, 79
- Kato, S., M. Takemori, S. Kitano, S. Hori, H. Fukushima, J. Numaga, H. Yamashita, Retinopathy in older patients with diabetes mellitus 58, 187
- Kavgaci, H., A. Sahin, H. Onder Ersoz, C. Erem, F. Ozdemir, The effects of losartan and fosinopril in hypertensive type 2 diabetic patients 58, 19
- Kawamori, R., see Shimizu, T. 58, 179
- Keleştimur, F., see Çetin, M. 58, 97
- Kennedy, A., see Willi, S.M. 58, 87
- Kira, S., see Miyatake, N. 58, 101
- Kitano, S., see Kato, S. 58, 187
- Kobayashi, J., T. Sasaki, Y. Ishiba, M. Watanabe, Clinical features of a young Japanese woman having marked obesity and abrupt onset of diabetes mellitus with ketoacidosis 58, 167
- Kobori, S., see Takahashi, T. 58, 123
- Koga, N., see Takahashi, T. 58, 123
- Kunitomi, M., see Miyatake, N. 58, 101
- Kyle, C., see Wong, J. 58, 61
- Li, G., Y. Hu, W. Yang, Y. Jiang, J. Wang, J. Xiao, Z. Hu, X. Pan, B.V. Howard, P.H. Bennett, Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study 58, 193
- Lopez, D., see Serra, A. 58, 149
- Love, D.R., see Wong, J. 58, 61
- Mafauzy, M., Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting 58, 45
- Makino, H., see Hasegawa, M. 58, 79
- Makino, H., see Miyatake, N. 58, 101
- Makita, Y., see Shimizu, T. 58, 179
- Marcocci, C., see Piaggese, A. 58, 1
- Minami, J., see Takahashi, T. 58, 123
- Miyatake, N., H. Nishikawa, A. Morishita, M. Kunitomi, J. Wada, H. Suzuki, K. Takahashi, H. Makino, S. Kira, M. Fujii, Daily walking reduces visceral adipose tissue areas and improves insulin resistance in Japanese obese subjects 58, 101
- Mojiminiyi, O.A., N. Abdella, M.A. Moussa, A.O. Akanji, H. Al Mohammedi, M. Zaki, Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus 58, 37
- Morishita, A., see Miyatake, N. 58, 101
- Mountjoy, K.G., see Wong, J. 58, 61
- Moussa, M.A., see Mojiminiyi, O.A. 58, 37
- Mullen, M., see Hirsch, I.B. 58, 27
- Nakagami, T., Q. Qiao, J. Tuomilehto, B. Balkau, B. Carstensen, N. Tajima, Y. Iwamoto, K. Borch-Johnsen, T.D.E.C.O.D.A.S.G. (on behalf of the International Diabetes Epidemiology Group), Corrigendum to "The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype": [Diabetes Res. Clin. Pract. 55 (2002) 35-43] 58, 73
- Neighbor, W.E., see Hirsch, I.B. 58, 27
- Nishikawa, H., see Miyatake, N. 58, 101
- Nishimiya, T., see Hasegawa, M. 58, 79
- Nord, E., see Persson, B. 58, 115
- Nordlander, E., see Persson, B. 58, 115
- Numaga, J., see Kato, S. 58, 187
- Ochi, M., see Hasegawa, M. 58, 79
- O'Dea, K., see Daniel, M. 58, 139
- (on behalf of the International Diabetes Epidemiology Group), T.D.E.C.O.D.A.S.G., see Nakagami, T. 58, 73
- Onder Ersoz, H., see Kavgaci, H. 58, 19
- Onuma, H., see Hasegawa, M. 58, 79
- Onuma, T., see Shimizu, T. 58, 179
- Osawa, H., see Hasegawa, M. 58, 79
- Ozdemir, F., see Kavgaci, H. 58, 19
- Pan, X., see Li, G. 58, 193
- Persson, B., M.-L. Swahn, R. Hjertberg, U. Hanson, E. Nord, E. Nordlander, L.-O. Hansson, Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus 58, 115
- Piaggese, A., L. Rizzo, F. Golia, D. Costi, F. Baccetti, S. Ciaccio, S. De Gregorio, E. Vignali, D. Trippi, V. Zampa, C. Marcocci, S. Del Prato, Biochemical and ultrasound tests for early diagnosis of active neuro-osteoarthropathy (NOA) of the diabetic foot 58, 1
- Qiao, Q., see Nakagami, T. 58, 73
- Ramachandran, A., C. Snehalatha, V. Vijay, Temporal changes in prevalence of type 2 diabetes and impaired glucose tolerance in urban southern India 58, 55
- Ramsey, S.D., see Hirsch, I.B. 58, 27
- Risbud, M.V., R.R. Bhonde, Models of pancreatic regeneration in diabetes 58, 155
- Rizzo, L., see Piaggese, A. 58, 1
- Rogers, N.L., see Willi, S.M. 58, 87
- Romero, R., see Serra, A. 58, 149
- Rowley, K.G., see Daniel, M. 58, 139
- Sahin, A., see Kavgaci, H. 58, 19
- Sakaue, M., see Danawati, W. 58, 201
- Sakka, Y., see Ujihara, N. 58, 109
- Sasaki, T., see Kobayashi, J. 58, 167
- Sato, Y., see Yamanouchi, K. 58, 11
- Schnell, A.H., see Wong, J. 58, 61
- Serra, A., R. Romero, B. Bayés, D. Lopez, J. Bonet, Is there a need for changes in renal biopsy criteria in proteinuria in type 2 diabetes? 58, 149

- Shichiri, M., see Yamanouchi, K. 58, 11
- Shimizu, T., T. Onuma, R. Kawamori, Y. Makita, Y. Tomino, Endothelial nitric oxide synthase gene and the development of diabetic nephropathy 58, 179
- Snehalatha, C., see Ramachandran, A. 58, 55
- Stewart, A.W., see Wong, J. 58, 61
- Suzuki, H., see Miyatake, N. 58, 101
- Swahn, M.-L., see Persson, B. 58, 115
- Tajima, N., see Nakagami, T. 58, 73
- Takahashi, C., see Ujihara, N. 58, 109
- Takahashi, K., see Miyatake, N. 58, 101
- Takahashi, T., M. Yano, J. Minami, T. Haraguchi, N. Koga, K. Higashi, S. Kobori, Sarpogrelate hydrochloride, a serotonin<sub>2A</sub> receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy 58, 123
- Takeda, A., see Yamanouchi, K. 58, 11
- Takeda, M., see Ujihara, N. 58, 109
- Takemori, M., see Kato, S. 58, 187
- Tang, Y., see Hasegawa, M. 58, 79
- Taniguchi, H., see Danawati, W. 58, 201
- Terauchi, Y., see Hasegawa, M. 58, 79
- Tomino, Y., see Shimizu, T. 58, 179
- Tomonaga, O., see Ujihara, N. 58, 109
- Trippi, D., see Piaggese, A. 58, 1
- Tuomilehto, J., see Nakagami, T. 58, 73
- Ujihara, N., Y. Sakka, M. Takeda, M. Hirayama, A. Ishii, O. Tomonaga, T. Babazono, C. Takahashi, K. Yamashita, Y. Iwamoto, Association between plasma oxidized low-density lipoprotein and diabetic nephropathy 58, 109
- Ünal, A., see Çetin, M. 58, 97
- Vignali, E., see Piaggese, A. 58, 1
- Vijay, V., see Ramachandran, A. 58, 55
- Wada, J., see Miyatake, N. 58, 101
- Wallace, P., see Willi, S.M. 58, 87
- Wang, J., see Li, G. 58, 193
- Watanabe, M., see Kobayashi, J. 58, 167
- Weerasuriya, N., see De Silva, S.N.T. 58, 173
- Wheeler, S.G., J.H. Ahroni, E.J. Boyko, Prospective study of autonomic neuropathy as a predictor of mortality in patients with diabetes 58, 131
- White, M., see Wong, J. 58, 61
- Willi, S.M., A. Kennedy, B.P. Brant, P. Wallace, N.L. Rogers, W.T. Garvey, Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes 58, 87
- Wong, J., D.R. Love, C. Kyle, A. Daniels, M. White, A.W. Stewart, A.H. Schnell, R.C. Elston, I.M. Holdaway, K.G. Mountjoy, Melanocortin-3 receptor gene variants in a Maori kindred with obesity and early onset type 2 diabetes 58, 61
- Xiao, J., see Li, G. 58, 193
- Yamanouchi, K., R. Abe, A. Takeda, Y. Atsumi, M. Shichiri, Y. Sato, The effect of walking before and after breakfast on blood glucose levels in patients with type 1 diabetes treated with intensive insulin therapy 58, 11
- Yamashita, H., see Kato, S. 58, 187
- Yamashita, K., see Ujihara, N. 58, 109
- Yang, W., see Li, G. 58, 193
- Yano, M., see Takahashi, T. 58, 123
- Zaki, M., see Mojiminiyi, O.A. 58, 37
- Zampa, V., see Piaggese, A. 58, 1



## Subject index of volume 58

**A controlled trial;** Multifaceted intervention; Diabetes treatment guidelines **58, 27**

**Adipocyte;** Phosphodiesterase 3B; IRS-1; Gene expression; Insulin resistance **58, 79**

**Agouti;** Melanocortin; Receptor; Chromosome; Diabetes; Maori; Obesity; New Zealand; Insulin; Proopiomelanocortin **58, 61**

**Albuminuria;** Diabetic nephropathy; Hypertension; Losartan; Fosinopril **58, 19**

**American Diabetes Association (ADA);** Diabetes mellitus; Tests; Screening; World Health Organisation (WHO); Diagnostic criteria; Indigenous; Australia **58, 139**

**Asian Indians;** Temporal change in diabetes; Impaired glucose tolerance; Type 2 diabetes; Urbanization; Lifestyle **58, 55**

**Australia;** Diabetes mellitus; Tests; Screening; American Diabetes Association (ADA); World Health Organisation (WHO); Diagnostic criteria; Indigenous **58, 139**

**Autonomic neuropathy;** Type 2 diabetes; Heart rate variability; Mortality; Prospective study **58, 131**

**Blood glucose control;** Type 1 diabetes; Intensive insulin therapy; Walking **58, 11**

**Charcot's foot;** Diabetes mellitus; Quantitative ultrasound; ICTP; Neuro-osteoarthropathy **58, 1**

**Chromosome;** Melanocortin; Receptor; Diabetes; Maori; Obesity; New Zealand; Insulin; Agouti; Proopiomelanocortin **58, 61**

**Constitutive endothelial nitric oxide synthase gene;** Diabetic nephropathy; Type 2 diabetes mellitus; Japanese **58, 179**

**C-Reactive protein;** Interleukin 6; Risk factors for coronary heart disease; Type 2 diabetes mellitus **58, 37**

**Daily waking;** Insulin resistance; Visceral adipose tissue **58, 101**

**Diabetes;** Melanocortin; Receptor; Chromosome; Maori; Obesity; New Zealand; Insulin; Agouti; Proopiomelanocortin **58, 61**

**Diabetes mellitus;** Charcot's foot; Quantitative ultrasound; ICTP; Neuro-osteoarthropathy **58, 1**

**Diabetes mellitus;** Diabetic retinopathy; Older patients; Proliferative diabetic retinopathy **58, 187**

**Diabetes mellitus, non-insulin dependent;** Diabetic retinopathy; Diabetic nephropathies; Haematuria; Renal biopsy **58, 149**

**Diabetes mellitus;** Obesity; Diabetic ketoacidosis; Lipoprotein lipase **58, 167**

**Diabetes mellitus;** Pancreatic cancer **58, 97**

**Diabetes mellitus;** Tests; Screening; American Diabetes Association (ADA); World Health Organisation (WHO); Diagnostic criteria; Indigenous; Australia **58, 139**

**Diabetes;** Pancreatic regeneration; Models **58, 155**

**Diabetes treatment guidelines;** Multifaceted intervention; A controlled trial **58, 27**

**Diabetic ketoacidosis;** Diabetes mellitus; Obesity; Lipoprotein lipase **58, 167**

**Diabetic nephropathies;** Diabetic retinopathy; Diabetes mellitus, non-insulin dependent; Haematuria; Renal biopsy **58, 149**

- Diabetic nephropathy;** Albuminuria; Hypertension; Losartan; Fosinopril **58**, 19
- Diabetic nephropathy;** Constitutive endothelial nitric oxide synthase gene; Type 2 diabetes mellitus; Japanese **58**, 179
- Diabetic nephropathy;** Oxidized low-density lipoprotein; Oxidized phosphatidylcholine **58**, 109
- Diabetic retinopathy;** Diabetic nephropathies; Diabetes mellitus, non-insulin dependent; Haematuria; Renal biopsy **58**, 149
- Diabetic retinopathy;** Older patients; Proliferative diabetic retinopathy; Diabetes mellitus **58**, 187
- Diagnostic criteria;** Diabetes mellitus; Tests; Screening; American Diabetes Association (ADA); World Health Organisation (WHO); Indigenous; Australia **58**, 139
- Effects;** Insulin; Resistance; Secretion; Efficacy; Intervention; type 2 Diabetes **58**, 193
- Efficacy;** Effects; Insulin; Resistance; Secretion; Intervention; type 2 Diabetes **58**, 193
- Excess maternal transmission;** Type 2 diabetes; Familial aggregation **58**, 173
- Familial aggregation;** Type 2 diabetes; Excess maternal transmission **58**, 173
- Fasting;** Prandial glucose regulation; Hypoglycaemia; Ramadan **58**, 45
- Fosinopril;** Diabetic nephropathy; Albuminuria; Hypertension; Losartan **58**, 19
- Free fatty acids;** Type 2 diabetes mellitus; Glucocorticoids; Thiazolidinedione; Troglitazone; Glucose tolerance; Leptin **58**, 87
- Gene expression;** Phosphodiesterase 3B; IRS-1; Insulin resistance; Adipocyte **58**, 79
- Glucocorticoids;** Type 2 diabetes mellitus; Thiazolidinedione; Troglitazone; Glucose tolerance; Free fatty acids; Leptin **58**, 87
- Glucose tolerance;** Type 2 diabetes mellitus; Glucocorticoids; Thiazolidinedione; Troglitazone; Free fatty acids; Leptin **58**, 87
- Haematuria;** Diabetic retinopathy; Diabetic nephropathies; Diabetes mellitus, non-insulin dependent; Renal biopsy **58**, 149
- Heart rate variability;** Type 2 diabetes; Autonomic neuropathy; Mortality; Prospective study **58**, 131
- Hypertension;** Diabetic nephropathy; Albuminuria; Losartan; Fosinopril **58**, 19
- Hypoglycaemia;** Prandial glucose regulation; Fasting; Ramadan **58**, 45
- ICTP;** Charcot's foot; Diabetes mellitus; Quantitative ultrasound; Neuro-osteoarthropathy **58**, 1
- Impaired glucose tolerance;** Temporal change in diabetes; Type 2 diabetes; Urbanization; Lifestyle; Asian Indians **58**, 55
- Indigenous;** Diabetes mellitus; Tests; Screening; American Diabetes Association (ADA); World Health Organisation (WHO); Diagnostic criteria; Australia **58**, 139
- Insulin;** Effects; Resistance; Secretion; Efficacy; Intervention; type 2 Diabetes **58**, 193
- Insulin lispro therapy;** Pregnancy; Type 1 diabetes mellitus **58**, 115
- Insulin;** Melanocortin; Receptor; Chromosome; Diabetes; Maori; Obesity; New Zealand; Agouti; Proopiomelanocortin **58**, 61
- Insulin resistance;** Daily waking; Visceral adipose tissue **58**, 101
- Insulin resistance;** Phosphodiesterase 3B; IRS-1; Gene expression; Adipocyte **58**, 79
- Intensive insulin therapy;** Type 1 diabetes; Walking; Blood glucose control **58**, 11
- Interleukin 6;** C-Reactive protein; Risk factors for coronary heart disease; Type 2 diabetes mellitus **58**, 37
- Intervention;** Effects; Insulin; Resistance; Secretion; Efficacy; type 2 Diabetes **58**, 193
- IRS-1;** Phosphodiesterase 3B; Gene expression; Insulin resistance; Adipocyte **58**, 79
- Japanese;** Constitutive endothelial nitric oxide synthase gene; Diabetic nephropathy; Type 2 diabetes mellitus **58**, 179
- Leptin;** Type 2 diabetes mellitus; Glucocorticoids; Thiazolidinedione; Troglitazone; Glucose tolerance; Free fatty acids **58**, 87
- Lifestyle;** Temporal change in diabetes; Impaired glucose tolerance; Type 2 diabetes; Urbanization; Asian Indians **58**, 55
- Lipoprotein lipase;** Diabetes mellitus; Obesity; Diabetic ketoacidosis **58**, 167

- Losartan**; Diabetic nephropathy; Albuminuria; Hypertension; Fosinopril 58, 19
- Maori**; Melanocortin; Receptor; Chromosome; Diabetes; Obesity; New Zealand; Insulin; Agouti; Proopiomelanocortin 58, 61
- Melanocortin**; Receptor; Chromosome; Diabetes; Maori; Obesity; New Zealand; Insulin; Agouti; Proopiomelanocortin 58, 61
- Microalbuminuria**; Serotonin2A receptor antagonist; Serotonin; Type 2 diabetes mellitus 58, 123
- Models**; Diabetes; Pancreatic regeneration 58, 155
- Mortality**; Type 2 diabetes; Autonomic neuropathy; Heart rate variability; Prospective study 58, 131
- Multifaceted intervention**; Diabetes treatment guidelines; A controlled trial 58, 27
- Neuro-osteoarthropathy**; Charcot's foot; Diabetes mellitus; Quantitative ultrasound; ICTP 58, 1
- New Zealand**; Melanocortin; Receptor; Chromosome; Diabetes; Maori; Obesity; Insulin; Agouti; Proopiomelanocortin 58, 61
- Obesity**; Diabetes mellitus; Diabetic ketoacidosis; Lipoprotein lipase 58, 167
- Obesity**; Melanocortin; Receptor; Chromosome; Diabetes; Maori; New Zealand; Insulin; Agouti; Proopiomelanocortin 58, 61
- Older patients**; Diabetic retinopathy; Proliferative diabetic retinopathy; Diabetes mellitus 58, 187
- Oxidized low-density lipoprotein**; Diabetic nephropathy; Oxidized phosphatidylcholine 58, 109
- Oxidized phosphatidylcholine**; Oxidized low-density lipoprotein; Diabetic nephropathy 58, 109
- Pancreatic cancer**; Diabetes mellitus 58, 97
- Pancreatic regeneration**; Diabetes; Models 58, 155
- Phosphodiesterase 3B**; IRS-1; Gene expression; Insulin resistance; Adipocyte 58, 79
- Prandial glucose regulation**; Hypoglycaemia; Fasting; Ramadan 58, 45
- Pregnancy**; Insulin lispro therapy; Type 1 diabetes mellitus 58, 115
- Proliferative diabetic retinopathy**; Diabetic retinopathy; Older patients; Diabetes mellitus 58, 187
- Proopiomelanocortin**; Melanocortin; Receptor; Chromosome; Diabetes; Maori; Obesity; New Zealand; Insulin; Agouti 58, 61
- Prospective study**; Type 2 diabetes; Autonomic neuropathy; Heart rate variability; Mortality 58, 131
- Quantitative ultrasound**; Charcot's foot; Diabetes mellitus; ICTP; Neuro-osteoarthropathy 58, 1
- Ramadan**; Prandial glucose regulation; Hypoglycaemia; Fasting 58, 45
- Receptor**; Melanocortin; Chromosome; Diabetes; Maori; Obesity; New Zealand; Insulin; Agouti; Proopiomelanocortin 58, 61
- Renal biopsy**; Diabetic retinopathy; Diabetic nephropathies; Diabetes mellitus, non-insulin dependent; Haematuria 58, 149
- Resistance**; Effects; Insulin; Secretion; Efficacy; Intervention; type 2 Diabetes 58, 193
- Risk factors for coronary heart disease**; C-Reactive protein; Interleukin 6; Type 2 diabetes mellitus 58, 37
- Screening**; Diabetes mellitus; Tests; American Diabetes Association (ADA); World Health Organisation (WHO); Diagnostic criteria; Indigenous; Australia 58, 139
- Secretion**; Effects; Insulin; Resistance; Efficacy; Intervention; type 2 Diabetes 58, 193
- Serotonin2A receptor antagonist**; Serotonin; Microalbuminuria; Type 2 diabetes mellitus 58, 123
- Serotonin**; Serotonin2A receptor antagonist; Microalbuminuria; Type 2 diabetes mellitus 58, 123
- Temporal change in diabetes**; Impaired glucose tolerance; Type 2 diabetes; Urbanization; Lifestyle; Asian Indians 58, 55
- Tests**; Diabetes mellitus; Screening; American Diabetes Association (ADA); World Health Organisation (WHO); Diagnostic criteria; Indigenous; Australia 58, 139
- Thiazolidinedione**; Type 2 diabetes mellitus; Glucocorticoids; Troglitazone; Glucose tolerance; Free fatty acids; Leptin 58, 87
- Troglitazone**; Type 2 diabetes mellitus; Glucocorticoids; Thiazolidinedione; Glucose tolerance; Free fatty acids; Leptin 58, 87

- Type 2 diabetes;** Autonomic neuropathy; Heart rate variability; Mortality; Prospective study **58**, 131
- type 2 Diabetes;** Effects; Insulin; Resistance; Secretion; Efficacy; Intervention **58**, 193
- Type 2 diabetes;** Excess maternal transmission; Familial aggregation **58**, 173
- Type 1 diabetes;** Intensive insulin therapy; Walking; Blood glucose control **58**, 11
- Type 2 diabetes mellitus;** Constitutive endothelial nitric oxide synthase gene; Diabetic nephropathy; Japanese **58**, 179
- Type 2 diabetes mellitus;** C-Reactive protein; Interleukin 6; Risk factors for coronary heart disease **58**, 37
- Type 2 diabetes mellitus;** Glucocorticoids; Thiazolidinedione; Troglitazone; Glucose tolerance; Free fatty acids; Leptin **58**, 87
- Type 1 diabetes mellitus;** Insulin lispro therapy; Pregnancy **58**, 115
- Type 2 diabetes mellitus;** Serotonin2A receptor antagonist; Serotonin; Microalbuminuria **58**, 123
- Type 2 diabetes;** Temporal change in diabetes; Impaired glucose tolerance; Urbanization; Lifestyle; Asian Indians **58**, 55
- Urbanization;** Temporal change in diabetes; Impaired glucose tolerance; Type 2 diabetes; Lifestyle; Asian Indians **58**, 55
- Visceral adipose tissue;** Daily waking; Insulin resistance **58**, 101
- Walking;** Type 1 diabetes; Intensive insulin therapy; Blood glucose control **58**, 11
- World Health Organisation (WHO);** Diabetes mellitus; Tests; Screening; American Diabetes Association (ADA); Diagnostic criteria; Indigenous; Australia **58**, 139

